Citizens Jmp assumed coverage on shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) in a report published on Tuesday morning, Marketbeat.com reports. The firm issued a mkt outperform rating on the stock.
Rapport Therapeutics Stock Performance
RAPP traded up $0.63 on Tuesday, reaching $9.26. The company had a trading volume of 121,600 shares, compared to its average volume of 179,539. Rapport Therapeutics has a 52-week low of $6.43 and a 52-week high of $29.74. The company has a market cap of $337.95 million and a price-to-earnings ratio of -0.67. The business has a 50 day simple moving average of $11.16 and a 200 day simple moving average of $17.11.
Insider Activity at Rapport Therapeutics
In related news, CFO Troy A. Ignelzi acquired 9,900 shares of the stock in a transaction on Wednesday, March 12th. The stock was purchased at an average price of $10.10 per share, for a total transaction of $99,990.00. Following the completion of the transaction, the chief financial officer now owns 9,900 shares of the company's stock, valued at $99,990. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Wendy B. Young purchased 6,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were purchased at an average price of $10.21 per share, with a total value of $61,260.00. Following the completion of the acquisition, the director now directly owns 6,000 shares in the company, valued at $61,260. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.
Institutional Trading of Rapport Therapeutics
A number of institutional investors have recently modified their holdings of RAPP. Charles Schwab Investment Management Inc. bought a new position in Rapport Therapeutics in the 3rd quarter worth $1,498,000. Geode Capital Management LLC bought a new stake in Rapport Therapeutics in the third quarter worth $4,133,000. State Street Corp purchased a new position in shares of Rapport Therapeutics in the 3rd quarter worth about $1,189,000. Jennison Associates LLC purchased a new stake in Rapport Therapeutics during the 4th quarter valued at about $1,105,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Rapport Therapeutics during the third quarter valued at approximately $34,000.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
